![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/ZYDUSLIFE.png)
Share the post "Zydus Lifesciences ‘s Q3 2024-25 Latest News: Profit Up by 29.92% Year-on-Year"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 16.96 % in the past year, substantial increase in net sales/revenue by 0.61 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 52.52 %. Marginal decrease of -15.69% in other income during this quarter. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Zydus Lifesciences Limited. Notable increase of 29.92 % in net profit Year to Year, Zydus Lifesciences Limited’s profitability increased by 11.52 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 30.38 % Year to Year. EPS increased by 12.25 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 4505.2 Cr | Rs. 5237 Cr | Rs. 5269.1 Cr | + 0.61 % | + 16.96 % |
| Expenses | Rs. 3402.8 Cr | Rs. 3775.6 Cr | Rs. 3881.5 Cr | + 2.8 % | + 14.07 % |
| Operating Profit | Rs. 1102.4 Cr | Rs. 1461.4 Cr | Rs. 1387.6 Cr | -5.05 % | + 25.87 % |
| OPM % | 24.47 % | 27.91 % | 26.33 % | -1.58 % | + 1.86 % |
| Other Income | Rs. 37.7 Cr | Rs. 68.2 Cr | Rs. 57.5 Cr | -15.69 % | + 52.52 % |
| Interest | Rs. 19.8 Cr | Rs. 25.1 Cr | Rs. 32 Cr | + 27.49 % | + 61.62 % |
| Depreciation | Rs. 194.8 Cr | Rs. 233.6 Cr | Rs. 229 Cr | -1.97 % | + 17.56 % |
| Profit before tax | Rs. 925.5 Cr | Rs. 1270.9 Cr | Rs. 1184.1 Cr | -6.83 % | + 27.94 % |
| Tax % | 23.1 % | 29.36 % | 15.16 % | -14.2 % | -7.94 % |
| Net Profit | Rs. 789.9 Cr | Rs. 920.2 Cr | Rs. 1026.2 Cr | + 11.52 % | + 29.92 % |
| EPS in Rs | Rs. 7.8 | Rs. 9.06 | Rs. 10.17 | + 12.25 % | + 30.38 % |
Today, we’re looking at Zydus Lifesciences Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 16.96 %. However, it did see a marginal increase of 0.61 % from the previous quarter. Expenses ticked up slightly by 2.8 % quarter-on-quarter, aligning with the annual rise of 14.07 %. Operating profit, while up 25.87 % compared to last year, faced a quarter-on-quarter dip of -5.05 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 1.86 %, but a shrinkage of -1.58 % sequentially. Other income fell by -15.69 % compared to the last quarter, despite an annual growth of 52.52 %. Interest expenses surged remarkably by 27.49 % from the previous quarter, yet the year-over-year increase remains at a moderate 61.62 %. Depreciation costs fell by -1.97 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 17.56 %. Profit before tax grew annually by 27.94 % but saw a reduction from the preceding quarter by -6.83 %.
Tax expenses as a percentage of profits decreased slightly by -7.94 % compared to last year, with a more notable quarter-on-quarter decrease of -14.2 %. Net profit rose by 29.92 % year-on-year but experienced a 11.52 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 30.38 % but a quarterly rise of 12.25 %. In summary, Zydus Lifesciences Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 4505.2 Cr | Rs. 5237 Cr | Rs. 5269.1 Cr | + 0.61 % | + 16.96 % |
| Expenses | Rs. 3402.8 Cr | Rs. 3775.6 Cr | Rs. 3881.5 Cr | + 2.8 % | + 14.07 % |
| Operating Profit | Rs. 1102.4 Cr | Rs. 1461.4 Cr | Rs. 1387.6 Cr | -5.05 % | + 25.87 % |
| Net Profit | Rs. 789.9 Cr | Rs. 920.2 Cr | Rs. 1026.2 Cr | + 11.52 % | + 29.92 % |
| EPS in Rs | Rs. 7.8 | Rs. 9.06 | Rs. 10.17 | + 12.25 % | + 30.38 % |
In reviewing Zydus Lifesciences Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 16.96 % year-on-year growth, however, there was a minor increase of 0.61 % from the previous quarter. Expenses rose by 14.07 % compared to the previous year, with a 2.8 % increase quarter-on-quarter. Operating Profit surged by 25.87 % annually, and saw a -5.05 % decrease from the last quarter.
Net Profit showed yearly increase of 29.92 %, and experienced a 11.52 % increase from the previous quarter. Earnings Per Share (EPS) rose by 30.38 % annually, however rose by 12.25 % compared to the last quarter. In essence, while Zydus Lifesciences Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
